CA 19-9
Also known as: Cancer Antigen 19-9, Carbohydrate Antigen 19-9
What Does CA 19-9 Measure?
CA 19-9 (Cancer Antigen 19-9, also called Carbohydrate Antigen 19-9) is a protein that exists on the surface of certain cells and is shed into the bloodstream. It is measured through a simple blood test that detects the concentration of this antigen in the serum. CA 19-9 is a carbohydrate structure (specifically a sialylated Lewis blood group antigen) that is normally produced in very small amounts by cells lining the pancreas, bile ducts, stomach, colon, and other gastrointestinal organs. Elevated levels in the blood can signal abnormal cellular activity, particularly related to certain cancers.
Why Does CA 19-9 Matter?
CA 19-9 is primarily used as a tumor marker to help monitor pancreatic cancer, the most common cancer associated with its elevation, as well as cancers of the bile ducts, gallbladder, stomach, and colon. It is not used alone for cancer diagnosis but serves as a valuable tool alongside imaging and other tests to monitor treatment response, detect recurrence after surgery, and assess disease progression. Elevated CA 19-9 can also occur in several benign (non-cancerous) conditions such as pancreatitis, liver disease, and biliary obstruction, which is why clinical context is critical when interpreting results. Notably, approximately 5-10% of the population lacks the Lewis antigen and will always test negative for CA 19-9 regardless of cancer status, making it an imperfect but still clinically useful marker.
Normal Ranges
Males
0–37 U/mL
Females
0–37 U/mL
Children
Generally <37 U/mL; not routinely measured in children
Causes of High Levels
- Pancreatic cancer – the most common malignant cause; levels above 1,000 U/mL are highly suspicious for advanced disease
- Cholangiocarcinoma (bile duct cancer) – tumors in the biliary tract frequently elevate CA 19-9
- Gallbladder cancer – malignant transformation of the gallbladder can significantly raise levels
- Colorectal and gastric cancers – gastrointestinal malignancies can produce moderate elevations
- Benign biliary obstruction or cholestasis – blockage of bile flow, even from gallstones, can temporarily raise levels
- Pancreatitis and liver cirrhosis – chronic or acute inflammation of the pancreas and liver disease can moderately elevate CA 19-9 without cancer
Causes of Low Levels
- Lewis antigen-negative genotype – approximately 5-10% of people genetically lack the Lewis (a-b-) antigen and will always have undetectable CA 19-9 levels
- Successful cancer treatment – effective surgery, chemotherapy, or radiation that reduces tumor burden will lower CA 19-9 toward normal
How to Improve Your CA 19-9
Diet
- Follow a plant-rich, anti-inflammatory diet emphasizing colorful vegetables, fruits, legumes, and whole grains to support overall gastrointestinal health
- Limit processed meats, red meat, and ultra-processed foods, which are associated with increased gastrointestinal cancer risk
- Reduce or eliminate alcohol consumption, as chronic alcohol use promotes pancreatitis and liver disease that can secondarily elevate CA 19-9
- Increase dietary fiber intake through foods like oats, beans, and cruciferous vegetables to support colon health and reduce colorectal cancer risk
- Stay well-hydrated and limit sugary beverages, as excess sugar intake is linked to obesity and metabolic conditions that elevate cancer risk
Supplements
- Curcumin (turmeric extract) 500–2,000 mg/day with piperine for enhanced bioavailability – has shown anti-inflammatory and potential anti-tumor properties in gastrointestinal research
- Omega-3 fatty acids (fish oil) 1,000–3,000 mg EPA+DHA daily – supports anti-inflammatory pathways and overall cell health
- Vitamin D3 1,000–4,000 IU daily (with physician guidance) – low vitamin D levels are associated with increased risk of several GI cancers including pancreatic cancer
Related Biomarkers
Frequently Asked Questions
Does a high CA 19-9 result mean I have cancer?
Not necessarily. While elevated CA 19-9 is associated with certain cancers, particularly pancreatic cancer, it can also be raised by benign (non-cancerous) conditions such as pancreatitis, gallstones, bile duct blockage, liver cirrhosis, and even some inflammatory bowel conditions. A single elevated result always requires further investigation with imaging studies (such as CT scan or MRI) and clinical evaluation by a physician before any diagnosis is made. CA 19-9 is not used as a standalone diagnostic test for cancer.
What CA 19-9 level is concerning for pancreatic cancer?
The standard upper limit of normal is 37 U/mL. Levels moderately above this (37–200 U/mL) can be seen in both benign and malignant conditions and require careful clinical evaluation. Levels above 200 U/mL raise greater concern for malignancy, and levels exceeding 1,000 U/mL are highly suggestive of advanced pancreatic or biliary cancer, though they can occasionally result from severe benign biliary obstruction. The trend of CA 19-9 over time (rising vs. falling) and correlation with imaging findings are more clinically meaningful than any single absolute value.
Can CA 19-9 be used for pancreatic cancer screening in healthy people?
No. CA 19-9 is not recommended as a general population screening tool for pancreatic cancer. It has insufficient sensitivity (it can be normal in early-stage cancer) and specificity (it can be elevated in benign conditions) for use as a standalone screening test in asymptomatic individuals. Additionally, 5-10% of people are genetically Lewis antigen-negative and will never produce measurable CA 19-9. Current guidelines reserve CA 19-9 primarily for monitoring known disease and treatment response, not for initial cancer detection.